Latest Ratios: P/E Ratio -0.0x · EV/EBITDA N/A · ROE -113.5%. (2018–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $9M | $28M | $134M | $124M | $88M | $402M | $1.2B | — | — |
| Enterprise Value | $649M | $668M | $621M | $576M | $629M | $1.0B | $1.4B | — | — |
| P/E Ratio → | -0.02 | — | — | — | — | — | — | — | — |
| P/S Ratio | 0.02 | 0.08 | 0.17 | 0.17 | 0.14 | 0.38 | 1.31 | — | — |
| P/B Ratio | — | — | 0.29 | 0.27 | 0.15 | 0.45 | 0.82 | — | — |
| P/FCF | — | — | — | 1.30 | 1.86 | — | — | — | — |
| P/OCF | — | — | — | 1.14 | 1.45 | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.84 | 0.78 | 0.78 | 1.00 | 0.95 | 1.60 | — | — |
| EV / EBITDA | — | — | 6.28 | 23.94 | — | — | 41.36 | — | — |
| EV / EBIT | — | — | 9.15 | — | — | — | — | — | — |
| EV / FCF | — | — | — | 6.04 | 13.28 | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 73.4% | 73.4% | 83.7% | 78.4% | 70.3% | 77.5% | 77.3% | 68.6% | 64.8% |
| Operating Margin | -42.3% | -42.3% | -0.9% | -11.1% | -50.4% | -46.1% | -7.4% | -6.1% | 12.7% |
| Net Profit Margin | -71.1% | -71.1% | -0.4% | -8.6% | -23.5% | -17.8% | -5.0% | -7.6% | 12.4% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | -113.5% | -113.5% | -0.6% | -12.1% | -20.0% | -16.5% | -3.9% | -12.1% | — |
| ROA | -20.8% | -20.8% | -0.2% | -4.0% | -8.0% | -9.1% | -2.4% | -4.7% | 19.7% |
| ROIC | -14.5% | -14.5% | -0.6% | -6.0% | -18.1% | -23.2% | -3.5% | -5.1% | — |
| ROCE | -15.3% | -15.3% | -0.6% | -6.5% | -19.6% | -25.5% | -3.7% | -4.1% | 30.3% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 1.15 | 1.19 | 0.94 | 0.78 | 0.29 | 0.34 | — |
| Debt / EBITDA | — | — | 5.34 | 22.56 | — | — | 11.78 | — | 0.14 |
| Net Debt / Equity | — | — | 1.06 | 0.99 | 0.91 | 0.69 | 0.18 | 0.32 | — |
| Net Debt / EBITDA | — | — | 4.93 | 18.79 | — | — | 7.54 | — | 0.13 |
| Debt / FCF | — | — | — | 4.74 | 11.41 | — | — | — | — |
| Interest Coverage | -4.74 | -4.74 | 0.93 | -1.18 | -5.58 | -14.94 | -1.95 | 5.65 | 126.71 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.02 | 2.02 | 1.18 | 1.29 | 1.56 | 1.98 | 3.08 | 1.27 | 1.13 |
| Quick Ratio | 2.02 | 2.02 | 1.18 | 1.29 | 1.56 | 1.98 | 3.08 | 1.27 | 1.13 |
| Cash Ratio | 0.23 | 0.23 | 0.12 | 0.25 | 0.06 | 0.39 | 1.13 | 0.11 | 0.01 |
| Asset Turnover | — | 0.37 | 0.54 | 0.49 | 0.38 | 0.51 | 0.42 | 0.34 | 1.58 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | 2.9% | — | — | 0.0% | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | 77.0% | 53.7% | — | — | — | — |
| Buyback Yield | 58.4% | 18.8% | 1.1% | 1.9% | 0.4% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 58.4% | 18.8% | 1.1% | 4.7% | 0.4% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $13M | $10M | $9M | $8M | $7M | $6M | $21M | $21M |
Includes 30+ ratios · 8 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying GOCO stock.
GoHealth Inc.'s current P/E ratio is -0.0x. This places it at the 50th percentile of its historical range.
GoHealth Inc.'s return on equity (ROE) is -113.5%. The historical average is -25.5%.
Based on historical data, GoHealth Inc. is trading at a P/E of -0.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
GoHealth Inc. has 73.4% gross margin and -42.3% operating margin.
Key Metrics
Top Statement Risk
Liquidity and Regulatory Headwinds
Metrics are mathematically derived from official filings.
Volatile Underwriting Profitability Metrics
As reported in recent financial filings, GoHealth's combined ratio has exhibited extreme volatility, swinging from 94.6% in 2023Q4 to 3.9% in 2026Q1, which suggests that the company's underwriting-related expense management is highly inconsistent and potentially distorted by non-recurring accounting adjustments rather than sustainable operational improvements.
The dramatic fluctuations in the combined ratio indicate that the company lacks a stable core underwriting margin, making it difficult to assess the true profitability of its brokerage activities. Investors should monitor whether these low ratios in recent quarters are sustainable or merely the result of aggressive expense deferrals that may reverse in future periods.
ROE Erosion and Structural Losses
Based on the provided financial data, GoHealth's return on equity has collapsed into deeply negative territory, reaching -149.3% in 2025Q4, which indicates that the company is currently unable to generate any meaningful return on its capital base while struggling with persistent operational deficits.
The negative ROE reflects a business model where the cost of acquiring customers consistently exceeds the present value of the commissions generated. This trend suggests that the company's pivot toward profitability is not yet reflected in its bottom-line performance, leaving shareholders with significant capital erosion.
Capital Base Under Severe Strain
According to recent balance sheet disclosures, the company's equity base has been severely depleted, with the P/B ratio turning negative at -7.82 in 2026Q1, a clear signal that the firm's liabilities now significantly exceed its tangible assets, leaving the capital structure in a highly vulnerable state.
The negative P/B ratio is a critical indicator of financial distress, suggesting that the market has effectively written off the book value of the firm. This leverage profile warrants further investigation into the company's ability to continue as a going concern without immediate capital injections or debt restructuring.
Misapplication of Combined Ratio Metrics
Analysts frequently misapply the combined ratio to GoHealth, failing to recognize that as a broker rather than a carrier, the metric is heavily distorted by LTV accounting, which obscures the actual cash-on-cash return of the company's marketing spend and its true underlying operational efficiency.
The combined ratio is designed for insurers bearing underwriting risk, whereas GoHealth's business is driven by commission-based revenue recognition under ASC 606. Investors should instead focus on the LTV/CAC ratio and actual cash collections to determine if the company is generating real liquidity or merely inflating its contract assets.